VCEL's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 295,568.8 -- higher than 100% of US-listed equities with positive expected earnings growth.
The price/operating cash flow metric for Vericel Corp is higher than 95.04% of stocks in our set with a positive cash flow.
VCEL's price/sales ratio is 7.61; that's higher than the P/S ratio of 82.75% of US stocks.
Stocks with similar financial metrics, market capitalization, and price volatility to Vericel Corp are AC, ZEN, GHM, PDFS, and PRSC.
Vericel Corporation focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company was founded in 1989 and is based in Cambridge, Massachusetts.
MediWound (MDWD) has popped up on my scanner several times over the past couple of years following some potent company press releases and catalysts. Admittedly, I would take a look at the headline and then check the ticker only to see a big move followed by a fade, so I...
DUBLIN--(BUSINESS WIRE)--The "Cell & Gene Therapy Market - Global Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering. In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included The study considers the present scenario of the cell and gene therapy market and its market dynamics for the period 2019-2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and suppl